Anna Julia Krupa

Dr. Anna Julia Krupa

Department of Affective Disorders, Medical College, Jagiellonian University, Kraków, Małopolskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2023 in Current Opinion in Psychiatry
Verified
Journal Article
Open access
Anna Julia KrupaAnna Julia Krupa
Anna Julia Krupa
DDDominika Dudek
Dominika Dudek
Marcin SiwekMarcin Siwek
Marcin Siwek
Purpose of review: The circular interactions between type 2 diabetes (TMD2) and major depressive disorder (MDD) are well documented but the understanding of their mechanisms has only recently gained more clarity. Latest research indicates, that the association between TMD2 and MDD is largely mediated by insulin resistance (IR). Recent findings: A metabolic subtype of MDD can be distinguished from other MDD subpopulations, that is characterized by predominantly atypical clinical presentation, IR and different responsiveness to antidepressant interventions. IR is a predictor of nonresponse to some antidepressants. The IR seems to be a state-marker of clinical or subclinical depression and the relationship between IR and MDD varies between sexes and ethnicities. Insulin has a direct impact on the monoaminergic systems known to underlie MDD symptoms: serotoninergic and dopaminergic, which are dysregulated in IR subjects. Several trials assessed the efficacy of insulin-sensitizing drugs in MDD with mixed results for metformin and more consistent evidence for pioglitazone and lifestyle intervention/physical activity. Summary: Recently published data suggest a significant role of IR in the clinical presentation, pathophysiology and treatment response in MDD. Further research of IR in MDD and integration of existing data into clinical practice are needed.

25 February 2023 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Marcin SiwekMarcin Siwek
Marcin Siwek
KWKrzysztof Wojtasik-Bakalarz
Krzysztof Wojtasik-Bakalarz
Anna Julia KrupaAnna Julia Krupa
Anna Julia Krupa
ACAdrian Chrobak
Adrian Chrobak
In 2002, the first III generation antipsychotic drug was registered—aripiprazole. Its partial dopaminergic agonism underlies its unique mechanism of action and the potentially beneficial influence on the positive, negative, or cognitive symptoms. Due to its relatively high intrinsic activity, the drug could often cause agitation, anxiety, or akathisia. For this reason, efforts were made to develop a drug which would retain the positive favorable actions of aripiprazole but present a more advantageous clinical profile. This turned out to be brexpiprazole, which was registered in 2015. Its pharmacodynamic and pharmacokinetic profile (similarly to the other most recent antipsychotics, i.e., lurasidone or cariprazine) shows promise of increasing the effectiveness of schizophrenia treatment in the dimensions in which the previous antipsychotics were not sufficiently effective, including negative, depressive, or cognitive symptoms. Like other new antipsychotics, it can also be useful in the treatment of mood disorders, for instance drug-resistant depression. Previous reviews focused on the use of brexpiprazole in specific diagnostic groups. The aim of this article is to provide the readers with an overview of data on the mechanism of action, clinical effectiveness in all studied diagnostic groups, as well as potential drug–food interactions, and the safety of brexpiprazole.

31 December 2023 in Psychiatria Polska
Verified
Journal Article
Open access
Anna Julia KrupaAnna Julia Krupa
Anna Julia Krupa
KWKrzysztof Wojtasik-Bakalarz
Krzysztof Wojtasik-Bakalarz
Marcin SiwekMarcin Siwek
Marcin Siwek
Wortioksetyna jest lekiem przeciwdepresyjnym o unikatowym profilu działań receptorowych. Zakres aktywności farmakodynamicznej wortioksetyny wiąże się nie tylko z modulacją przekaźnictwa serotoninergicznego, ale także noradrenergicznego i dopaminergicznego. Jednocześnie charakterystyka farmakokinetyczna leku warunkuje jego wysoką tolerancję i bezpieczeństwo, które obserwowano także wśród pacjentów w podeszłym wieku lub u osób obciążonych schorzeniami somatycznymi. Celem tej pracy jest podsumowanie wiedzy pochodzącej z najnowszych badań oceniających efekty leczenia wortioksetyną. Skuteczność wortioksetyny w terapii depresji potwierdzono w wielu badaniach otwartych, randomizowanych próbach z grupą kontrolą oraz ich metaanalizach. Najnowsze badania wskazują ponadto, że lek ten pozwala chorym z depresją nie tylko na osiągnięcie remisji objawowej, ale także na uzyskanie poprawy hedonii oraz funkcjonowania poznawczego i zawodowego. Opisywano także badania potwierdzające skuteczność wortioksetyny w leczeniu osób, które doświadczyły traumy, pacjentów z depresją w przebiegu choroby dwubiegunowej, a także chorych w wieku podeszłym. Wortioksetyna charakteryzuje się korzystnym profilem tolerancji, rzadko powodując poważne działania niepożądane i wysokim bezpieczeństwem terapii.

9 July 2024 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
Anna Julia KrupaAnna Julia Krupa
Anna Julia Krupa
ACAdrian Chrobak
Adrian Chrobak
ZSZbigniew Sołtys
Zbigniew Sołtys
DDDominika Dudek
Dominika Dudek
Bernadeta SzewczykBernadeta Szewczyk
Bernadeta Szewczyk
Marcin SiwekMarcin Siwek
Marcin Siwek
Background: The understanding of mechanisms underlying non-response to antidepressants is limited. The latest data highlights the role of insulin resistance (IR) in major depressive disorder (MDD) pathophysiology, presentation, and treatment efficacy. This work aimed to assess IR in MDD and explore the relationships between IR, MDD presentation and non-response to selective serotonin and noradrenaline reuptake inhibitors (SNRI). Methods: 67 MDD individuals: 36 responsive (MDD T[+]), 31 non-responsive (MDD T[−]) to SNRI and 30 healthy controls were recruited. The treatment response criteria were: Clinical Global Impression Scale-Improvement score of 1 or 2 after ≥ 8 weeks of treatment. Participants were assessed by physician and self-report tools measuring depression, anhedonia, anxiety, bipolarity, sleep quality. Blood samples were collected to assess fasting glucose and insulin levels and calculate HOMA-IR (homeostasis model assessment of insulin resistance). Results: MDD T[-] vs. MDD T[+] had significantly higher body mass index, insulin levels, and HOMA-IR. MDD T[-] presented higher levels of depressed mood, appetite/weight changes, loss of interest, energy, overall depressive symptoms, and sleep impairment; some evaluations suggested higher anhedonia and anxiety in MDD T[-] vs. MDD T[+]. Insulin and IR were weakly but significantly correlated with the severity of psychomotor symptoms, energy level, thoughts of death/suicide, self-criticism, appetite/weight, depressed mood symptoms, sleep problems. IR was weakly but significantly correlated with anhedonia. Conclusion: IR appears to be linked to depressive symptoms characteristic of the “metabolic” MDD subtype, such as psychomotor changes, energy level, anhedonia, sleep problems, appetite/weight changes, state and trait anxiety, sleep quality, and non-response to SNRI.

1 November 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
DDDominika Dudek
Dominika Dudek
ACAdrian Andrzej Chrobak
Adrian Andrzej Chrobak
Anna Julia KrupaAnna Julia Krupa
Anna Julia Krupa
AGAleksandra Gorostowicz
Aleksandra Gorostowicz
AGAdrian Gerlich
Adrian Gerlich
Marcin SiwekMarcin Siwek
Marcin Siwek
Introduction: Selective serotonin reuptake inhibitors (SSRIs) are the most often used medications to treat major depressive disorder (MDD). Despite their effectiveness in reducing depressive symptoms, several issues are associated with their use in MDD, such as limited improvement of anhedonia, emergence of emotional blunting, induction or exacerbation of insomnia, and sexual dysfunction. Due to its also devoid of the issues related to treatment noted with SSRIs. The aim of this 12-week non-inferiority naturalistic observation was to compare the effectiveness and tolerability of SSRIs and trazodone in extended release (XR) in MDD.Methods: A total of 186 subjects were recruited, of which 92 received trazodone XR and 94 received SSRIs. Patients were allocated to trazodone XR or SSRIs, according to the attending physician based on clinical evaluation. Assessments at baseline and weeks 2, 4, 8, and 12 were conducted to evaluate the severity of depression (Montgomery–Åsberg Depression Rating Scale, clinician- and patient-rated Quick Inventory of Depressive Symptomatology—the primary endpoints of the study), anhedonia (the Snaith–Hamilton Pleasure Scale), anxiety (the Hamilton Anxiety Rating Scale), insomnia (the Athens Insomnia Scale), and therapeutic effectiveness (the Clinical Global Impression Scale).Results: After 12 weeks, trazodone XR was more effective than SSRIs in reducing the severity of depression, anxiety, and insomnia. There was a trend for higher effectiveness of in reduction of anhedonia, which became insignificant after controlling the results for the duration of previous psychiatric treatment as a covariate. The proportion of treatment-responsive subjects in the trazodone XR group compared to SSRIs was comparable or higher. The proportion of patients achieving remission was higher in the trazodone XR arm vs. the SSRI arm.Discussion: In summary, the results indicate that trazodone XR is effective in MDD in the “real-world” setting. Its potential superiority over SSRIs in addressing particular symptomatic dimensions should be verified in future studies.

1 June 2021 in Journal of Psychiatric Research
Verified
Journal Article
Closed access
ACAdrian Andrzej Chrobak
Adrian Andrzej Chrobak
Anna Julia KrupaAnna Julia Krupa
Anna Julia Krupa
DDDominika Dudek
Dominika Dudek
Marcin SiwekMarcin Siwek
Marcin Siwek